Alembic Pharmaceuticals (APLLTD) investor relations material

Executive summary

• Q1 FY27 consolidated revenue grew 26% year-over-year to INR 2,150 crore, driven by strong performance across all major businesses, especially U.S. generics and animal health.

• Net profit rose 12% year-over-year to INR 173 crore, with a net profit margin of 8%.

• U.S. generics business grew 49% year-over-year, aided by volume growth, new launches, and 180-day exclusivity on bosutinib.

• India branded business grew 7%, with animal health up 24% and specialty therapies performing well.

• Strategic expansion in the U.S., robust R&D pipeline, and continued investments in manufacturing and branded platforms supported profitability.

Financial highlights

• Revenue reached INR 2,150 crore, up 26% year-over-year, with 16% EBITDA margin and 8% PAT margin.

• EBITDA grew 21% year-over-year to INR 348 crore; gross margin stable at 71%.

• Profit before tax increased 17% year-over-year to INR 223 crore.

• R&D expenditure was INR 186 crore, about 9% of revenue.

• Earnings per share (consolidated) for Q1 FY27 was ₹8.80.

Outlook and guidance

• U.S. generics growth guidance raised to mid to high teens for FY27, with 15+ product launches planned.

• Overall company growth outlook improved to mid-teen range for FY27.

• India business expected to align with market growth, aiming for high single-digit to low double-digit growth.

• ROW business guided for 15% INR growth, with confidence in sustaining momentum.

• Ongoing investment in R&D and specialty drug development for India and international markets.